Last update 08 May 2025

Myeloablative Hematopoietic Stem Cell (Rho Federal Systems Division)

Overview

Basic Info

Drug Type
Hematopoietic stem cell therapy
Synonyms-
Target-
Action-
Mechanism
Stem cell replacements
Therapeutic Areas
Immune System DiseasesSkin and Musculoskeletal DiseasesOther Diseases
Active Indication-
Inactive Indication
Scleroderma, Systemic
Originator Organization
Rho Federal Systems Division, Inc.
Active Organization-
Inactive Organization
Rho Federal Systems Division, Inc.
License Organization-
Drug Highest PhasePendingPhase 2/3
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Myeloablative Hematopoietic Stem Cell (Rho Federal Systems Division)
NCT00114530
/ CompletedPhase 2/3IIT
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
100 Clinical Results associated with Myeloablative Hematopoietic Stem Cell (Rho Federal Systems Division)
Login to view more data
100 Translational Medicine associated with Myeloablative Hematopoietic Stem Cell (Rho Federal Systems Division)
Login to view more data
100 Patents (Medical) associated with Myeloablative Hematopoietic Stem Cell (Rho Federal Systems Division)
Login to view more data
100 Deals associated with Myeloablative Hematopoietic Stem Cell (Rho Federal Systems Division)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Scleroderma, SystemicPhase 3
Canada
Rho Federal Systems Division, Inc.
01 Jun 2005
Scleroderma, SystemicPhase 3
United States
Rho Federal Systems Division, Inc.
01 Jun 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT00114530 (SCOT, CTgov)
Phase 2/3
Scleroderma, Systemic
75
(mHSCT)
aqbjtojxbu(dewvjwzqdo) = wmpsmkvivp xaiuekgfmw (lzxildrzry, agrjlcxbzq - ydlpbemfgm)
View more
-
14 Jul 2017
(Cyclophosphamide)
aqbjtojxbu(dewvjwzqdo) = azeuyvausu xaiuekgfmw (lzxildrzry, avoabvyqpj - iayohtgsga)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free